Abstract: The invention relates to compositions comprising NaturalKiller (NK) cells and ?? T cells, particularly for use in adoptive immunotherapy. The invention also provides method for preparing such compositions which comprises contacting a sample with an anti-TCR delta variable 1 (anti-V?1) antibody.
Type:
Application
Filed:
September 4, 2021
Publication date:
October 19, 2023
Applicant:
GAMMADELTA THERAPEUTICS LIMITED
Inventors:
Timothy RECALDIN, Andre SIMOES, Oliver NUSSBAUMER, Istvan KOVACS, Mihil PATEL
Abstract: The invention relates to methods for the isolation of non-haematopoietic tissue-resident lymphocytes, particularly ?? T cells. Such ?? T cells include non-V?2 cells, e.g. V?1, V?3 and V?5 cells and such non-haematopoietic tissues include skin and gut. It will be appreciated that such isolated non-haematopoietic tissue-resident lymphocytes find great utility in adoptive T cell therapies, chimeric receptor therapies and the like. Also provided are methods for expanding isolated tissue-resident lymphocytes, particularly methods for isolating and expanding ?? T cells. The present invention also relates to both individual cells and populations of cells produced by the methods described herein.
Type:
Application
Filed:
May 12, 2021
Publication date:
July 20, 2023
Applicant:
GAMMADELTA THERAPEUTICS LIMITED
Inventors:
Madeline DALZIEL, Andrew HUTTON, Sean O'FARRELL, Oliver NUSSBAUMER
Abstract: The invention relates to ex vivo methods of modulating gamma variable 4 (V?4) T cells using antibodies or fragments thereof, which specifically bind to a V?4 chain of a ?? T cell receptor (TCR) and not to a gamma variable 2 (V?2) chain of a ?? TCR. Methods of treatment and other uses of expanded populations of V?4 T cells produced by said methods are also provided.
Type:
Application
Filed:
February 24, 2021
Publication date:
May 25, 2023
Applicant:
GAMMADELTA THERAPEUTICS LIMITED
Inventors:
Oliver NUSSBAUMER, Oxana POLYAKOVA, Adrian HAYDAY, Pierre VANTOUROUT
Abstract: The invention relates to compositions comprising V?1+ T cells, for use in treating myeloid malignancies. The present invention also relates to methods of treatment using said compositions.
Type:
Application
Filed:
March 20, 2020
Publication date:
May 18, 2023
Applicant:
GammaDelta Therapeutics Limited
Inventors:
Andre Goncalo do Espirito Santo SIMOES, Biagio DI LORENZO, Michael KOSLOWSKI, Bruno Miguel de Carvalho e SILVA-SANTOS, Andrew John HUTTON, Timothy Joel RECALDIN, Daniel FOWLER, Alice BROMLEY, Oliver NUSSBAUMER
Abstract: An isolated antibody or fragment thereof, which specifically binds to a gamma variable 4 (V?4) chain of a ?? T cell receptor (TCR) and not to a gamma variable 2 (V?2) chain of a ?? TCR is provided herein. Methods of treatment and other uses of said antibodies are also provided along with methods of producing said antibodies.
Type:
Application
Filed:
February 24, 2021
Publication date:
March 23, 2023
Applicant:
GammaDelta Therapeutics Limited
Inventors:
Oxana Polyakova, Oliver Nussbaumer, Adrian Hayday, Pierre Vantourout
Abstract: The present invention provides methods of expanding ?? T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded ?? T cells and methods of using the expanded ?? T cells (e.g., apart of an adoptive T cell therapy).
Type:
Application
Filed:
May 3, 2018
Publication date:
March 25, 2021
Applicants:
King's College London, GammaDelta Therapeutics Limited, GammaDelta Therapeutics Limited
Inventors:
Richard BEATSON, Adrian HAYDAY, Oliver NUSSBAUMER, Richard WOOLF, Maria Luisa IANNITTO, Natalie MOUNT